A phase II clinical trial was initiated in 2017 to determine its clinical efficiency and safety in combination with chemotherapy and trastuzumab in Her2+ metastatic breast cancer or when combined with endocrine treatment in ER+ breast tumors [87]. The gene discussed is ERBB2; the disease is breast neoplasm.